UCB and Biogen’s drug dapirolizumab pegol has met the primary endpoint of improvement in disease activity in lupus patients.

Dapirolizumab pegol is an investigational Fc-free polyethylene glycol-conjugated antigen-binding fragment that inhibits CD40 ligand signaling.

UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...

Objective To identify differentially expressed genes in temporal artery biopsies (TABs) from patients with giant cell arteritis (GCA) with different histological patterns of inflammation: transmural ...